Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew W Roberts

Showing results (131-140 of 198) with videos related to

Pageof 20
Sort By:
Cancer Cell|November 14, 2006
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralizedMark F van Delft, Andrew H Wei, Kylie D Mason, et al.
Blood Advances|September 3, 2021
Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibitionThomas E Lew, Victor S Lin, Edward R Cliff, et al.
Nature Communications|June 5, 2019
Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutationsRichard W Birkinshaw, Jia-Nan Gong, Cindy S Luo, et al.
Leukemia|June 24, 2025
Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practicePiers Blombery, Thomas Chatzikonstantinou, Marina Gerousi, et al.
Blood Advances|January 17, 2024
Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommonThomas E Lew, Rory Bennett, Victor S Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2018
Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic LeukemiaMatthew S Davids, Michael Hallek, William Wierda, et al.
Nature Immunology|May 20, 2003
SOCS3 negatively regulates IL-6 signaling in vivoBen A Croker, Danielle L Krebs, Jian-Guo Zhang, et al.
Blood|January 18, 2020
Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclaxPiers Blombery, Ella R Thompson, Tamia Nguyen, et al.
Blood|June 11, 2021
Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapyShuo Ma, John F Seymour, Danielle M Brander, et al.
Leukemia & Lymphoma|July 15, 2021
Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD)Anna Kalff, Tiffany Khong, Malarmathy Ramachandran, et al.
Pageof 20

Showing results (131-140 of 198) with videos related to

Sort By:
Pageof 20
Cancer Cell|November 14, 2006
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralizedMark F van Delft, Andrew H Wei, Kylie D Mason, et al.
Blood Advances|September 3, 2021
Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibitionThomas E Lew, Victor S Lin, Edward R Cliff, et al.
Nature Communications|June 5, 2019
Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutationsRichard W Birkinshaw, Jia-Nan Gong, Cindy S Luo, et al.
Leukemia|June 24, 2025
Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practicePiers Blombery, Thomas Chatzikonstantinou, Marina Gerousi, et al.
Blood Advances|January 17, 2024
Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommonThomas E Lew, Rory Bennett, Victor S Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2018
Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic LeukemiaMatthew S Davids, Michael Hallek, William Wierda, et al.
Nature Immunology|May 20, 2003
SOCS3 negatively regulates IL-6 signaling in vivoBen A Croker, Danielle L Krebs, Jian-Guo Zhang, et al.
Blood|January 18, 2020
Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclaxPiers Blombery, Ella R Thompson, Tamia Nguyen, et al.
Blood|June 11, 2021
Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapyShuo Ma, John F Seymour, Danielle M Brander, et al.
Leukemia & Lymphoma|July 15, 2021
Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD)Anna Kalff, Tiffany Khong, Malarmathy Ramachandran, et al.
Pageof 20